Article Details

Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies

Retrieved on: 2017-12-13 19:07:09

Tags for this article:

Click the tags to see associated articles and topics

Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies. View article details on hiswai:

Excerpt

<div>Boston biotech Kyn Therapeutics has raised $49 million in a Series A round to advance its immunometabolism therapies to treat cancer. The money comes from <b>Atlas Venture</b> and OrbiMed — both repeat investors who first funded the company during its launch last March. Mark Manfredi. Kyn is led by an ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up